Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission September 29, 2026 8:30 AM EDT
Company Participants
Katie Falzone – Senior Vice President of Finance
Marc Elia – CEO & Chairperson of the Board
Michael Mina – Chief Medical Officer & Chief Epidemiologist
Conference Call Participants
Joshua Schimmer – Cantor Fitzgerald & Co., Research Division
Thomas Shrader – BTIG, LLC, Research Division
Luis Santos – H.C. Wainwright & Co, LLC, Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Invivyd Topline LIBERTY Data and VYD2311 Next Steps, September 29, 2026. [Operator Instructions] Please be advised that today’s conference is being recorded.
And I would now like to hand the conference over to your first speaker today, Katie Falzone. Please go ahead.
Katie Falzone
Senior Vice President of Finance
Thank you, operator. A short while ago, we issued a press release announcing an update on our LIBERTY Phase III study and VYD2311 regulatory submission plans. That press release and the slides that are being used on today’s webcast can be found in the Investors section of the Invivyd website under the Press Release and Events and Presentations sections, respectively. Today’s discussion will be led by Marc Elia, Chairman and Chief Executive Officer of Invivyd. He is joined by Dr. Michael Mina, Chief Medical Officer and Chief Epidemiologist of Invivyd.
During today’s discussion, we will be making forward-looking statements concerning, among other things, our research and development activities, our regulatory plans, our future prospects, and other statements that are not historical facts. These forward-looking statements are covered within the meaning of the Private Securities Litigation Reform Act and are subject to various risks, assumptions and uncertainties that may change over time and cause our actual results to differ materially from those expressed or implied today. These forward-looking statements speak only
